Journal of Environmental Pathology, Toxicology and Oncology

ISSN for PRINT: 0731-8898

For Online Access

Best Paper Award Selection - Editorial Board Site

2005, Volume24

Issue 4

112 pages

Issue price - $160.00

Do-Hee Kim
National Research Laboratory of Molecular Carcinogenesis and Chemoprevention, College of Pharmacy, Seoul National University, Seoul, South Korea

Hye-Kyung Na
National Research Laboratory of Molecular Carcinogenesis and Chemoprevention, College of Pharmacy, Seoul National University, Seoul, South Korea

Tae Young Oh
Dong-A Pharmaceutical Co. Ltd., Kyunggido, South Korea

Chang-Yell Shin
Dong-A Pharmaceutical Co. Ltd., Kyunggido, South Korea

Young-Joon Surh, Ph.D., Professor
National Research Laboratory of Molecular Carcinogenesis and Chemoprevention, College of Pharmacy Seoul National University Shinlim-dong, Kwanak-gu Seoul 151-742 South Korea

Artemisia asiatica Nakai has been used frequently in traditional Asian medicine for the treatment of inflammation and cancer. Eupatilin (5,7-dihydroxy-3′,4′, 6-trimethoxy-flavone) was shown to be a pharmacologically active ingredient of A. asiatica. In the present study, we found that expression of cyclin D1, a key protein that regulates G₁/S progression, was decreased in MCF-10A-ras cells treated with eupatilin. Downregulation of cyclin D1 expression by eupatilin was accompanied by a reduced expression of c-Jun and the DNA binding activity of the transcription factor AP-l. The expression of p21^waf1/Cip1 was also decreased by eupatilin treatment in both protein and the mRNA levels. We concluded that the inhibitory effect of eupatilin on p21^waf1/Cip1 expression is likely to be associated with the downregulation of cyclin D1 expression and AP-1 activation, which play an important role in the cell cycle arrest of ras-transformed breast epithelial cells.

Download article, 251-260 pages

Article price - $35.00

<< Previous article   Next article >>